Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce “Gonzalez”?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matt Herper joins us to break down the Senate Finance Committee hearing that saw seven pharmaceutical executives taken to task on the topic of drug pricing. Then, Matt sticks around to talk about what a spate of billion-dollar deals mean for the future of biotech. Later, STAT reporter Kate Sheridan stops by to talk about what you can — and can’t — learn about stealthy biotech startups when you do a little digging. Finally, we embark upon a lightning round that touches on Bristol-Myers Squibb’s increasingly difficult quest to buy Celgene, a controversial effort toward gender parity, and some unwanted brand recognition for Novartis.
For more on what we cover, here’s a recap of the hearing; here’s how the executives fared in the spotlight; here’s the latest on biotech buyouts; and here’s Kate’s most recent column.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].